COYA — Coya Therapeutics Balance Sheet
0.000.00%
- $106.54m
- $68.20m
- $3.55m
- 39
- 12
- 85
- 42
Annual balance sheet for Coya Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 8.72 | 4.34 | 5.93 | 32.6 | 38.3 |
Net Total Receivables | 0.001 | 0 | — | 7.5 | 0.731 |
Prepaid Expenses | |||||
Total Current Assets | 8.75 | 4.58 | 7.18 | 41.2 | 44.3 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0 | 0.121 | 0.093 | 0.066 | 0.039 |
Other Long Term Assets | |||||
Total Assets | 8.75 | 4.79 | 8.4 | 41.3 | 44.3 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.447 | 1.15 | 3.82 | 5.05 | 3.82 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.447 | 1.15 | 16.8 | 5.63 | 4.77 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 8.3 | 3.64 | -8.39 | 35.6 | 39.6 |
Total Liabilities & Shareholders' Equity | 8.75 | 4.79 | 8.4 | 41.3 | 44.3 |
Total Common Shares Outstanding |